Tags : LusiNEX

Biosimilars

Mycenax Signs an Agreement with Gedeon Richter for LusiNEX

Shots: Mycenax to sell LusiNEX project, including cell banks, CMC technology, intellectual properties, and clinical trial results to Gedeon Richter making a total deal value $16.5M. Mycenax to get payments as it completes the stages of asset transfer which will be utilized to operation and facility expansion which further strengthen Mycenax’s capacities in CDMO business […]Read More